Ocular Historical Income Statement
| OCUL Stock | USD 9.89 0.17 1.69% |
Historical analysis of Ocular Therapeutix income statement accounts such as Selling And Marketing Expenses of 42.6 M can show how well Ocular Therapeutix performed in making a profits. Evaluating Ocular Therapeutix income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ocular Therapeutix's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Ocular Therapeutix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ocular Therapeutix is a good buy for the upcoming year.
Ocular |
About Ocular Income Statement Analysis
Ocular Therapeutix Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ocular Therapeutix shareholders. The income statement also shows Ocular investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Ocular Therapeutix Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Ocular Therapeutix generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Ocular Therapeutix minus its cost of goods sold. It is profit before Ocular Therapeutix operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Ocular Therapeutix's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ocular Therapeutix current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.At this time, Ocular Therapeutix's Total Other Income Expense Net is quite stable compared to the past year. Income Tax Expense is expected to rise to about 3 M this year, although the value of Selling General Administrative will most likely fall to about 19 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 6.7M | 7.0M | 11.3M | 11.9M | Depreciation And Amortization | 2.4M | 2.1M | 3.0M | 1.6M |
Ocular Therapeutix income statement Correlations
Click cells to compare fundamentals
Ocular Therapeutix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ocular Therapeutix income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.2M | 2.8M | 2.4M | 2.1M | 3.0M | 1.6M | |
| Interest Expense | 6.1M | 6.8M | 6.7M | 7.0M | 11.3M | 11.9M | |
| Selling General Administrative | 22.1M | 22.9M | 31.9M | 32.2M | 33.9M | 19.0M | |
| Selling And Marketing Expenses | 24.5M | 26.6M | 35.2M | 39.9M | 40.5M | 42.6M | |
| Total Revenue | 4.2M | 17.4M | 43.5M | 51.5M | 58.4M | 61.4M | |
| Gross Profit | 1.9M | 15.3M | 39.1M | 47.0M | 53.2M | 55.8M | |
| Other Operating Expenses | 90.0M | 80.3M | 121.6M | 130.1M | 140.8M | 75.8M | |
| Operating Income | (85.8M) | (62.8M) | (78.0M) | (78.7M) | (82.4M) | (86.5M) | |
| Ebit | (85.8M) | (148.9M) | (78.0M) | (64.0M) | (69.4M) | (72.9M) | |
| Research Development | 41.1M | 28.7M | 50.1M | 53.5M | 61.1M | 36.4M | |
| Ebitda | (84.6M) | (146.1M) | (75.6M) | (61.9M) | (66.4M) | (69.7M) | |
| Cost Of Revenue | 2.3M | 2.1M | 4.4M | 4.5M | 5.3M | 5.5M | |
| Total Operating Expenses | 87.7M | 78.2M | 117.2M | 125.6M | 135.5M | 74.0M | |
| Income Before Tax | (86.4M) | (155.6M) | (6.6M) | (71.0M) | (80.7M) | (84.8M) | |
| Total Other Income Expense Net | (570K) | (92.8M) | 71.5M | 7.6M | 1.6M | 1.7M | |
| Net Income | (89.9M) | (159.6M) | (10.8M) | (63.4M) | (80.7M) | (84.8M) | |
| Income Tax Expense | 3.6M | 4.0M | 4.3M | (7.6M) | 2.8M | 3.0M | |
| Net Income From Continuing Ops | (86.4M) | (155.6M) | (6.6M) | (71.0M) | (67.1M) | (70.4M) | |
| Non Operating Income Net Other | 5.5M | (86.0M) | 78.2M | 14.6M | 16.8M | 17.7M | |
| Net Income Applicable To Common Shares | (86.4M) | (155.6M) | (6.6M) | (71.0M) | (63.9M) | (67.1M) | |
| Interest Income | 1.2M | 168K | 33K | 798K | 2.9M | 3.1M | |
| Net Interest Income | (4.9M) | (6.6M) | (6.6M) | (6.2M) | (6.1M) | (6.4M) | |
| Reconciled Depreciation | 2.5M | 2.8M | 2.4M | 2.1M | 2.5M | 2.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.